Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
Sponsor: Arrevus Inc.
Listed as NCT02569541, this PHASE2/PHASE3 trial focuses on Refractory Bone or Joint Infections and remains completed. Sponsored by Arrevus Inc., it has been updated 12 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 7 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
May 2019 — Feb 2020 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arrevus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .